InspireMD Reports Q2 2025 Earnings with FDA Approval and Revenue Growth
InspireMD (NSPR) reported Q2 2025 earnings with $1.8 million in revenue, a 2% increase driven by international CGuard adoption and favorable foreign exchange. The company received FDA premarket approval for its CGuard Prime Carotid Stent System, allowing a U.S. commercial launch, but reported a net loss of $13.2 million due to increased operating expenses and foreign exchange losses.
Tickers: $NSPR
Topics: Commercial Launch FDA Approval Gross Profit Net Loss Operating Expenses Revenue